Table 2 Use of medication against allergy during the most recent grass pollen season (n (%))
Completed (n = 107) | On treatment (n = 55) | Discontinued (n = 45) | p-value | |
|---|---|---|---|---|
No medication | 9 (8%) | 3 (5%) | 3 (7%) | 0.78 |
Oral antihistamines | 86 (80%) | 50 (91%) | 39 (87%) | 0.19 |
Montelukast | 9 (8% | 14 (25%) | 9 (20%) | 0.01 |
Oral corticosteroids | 6 (6%) | 3 (5%) | 3 (7%) | 0.96 |
Nasal antihistamines | 11 (10%) | 13 (24%) | 6 (13%) | 0.07 |
Nasal corticosteroids | 49 (46%) | 33 (60%) | 24 (53%) | 0.22 |
Nasal cromoglycate | 5 (5%) | 1 (2%) | 5 (11%) | 0.11 |
Antihistamine eyedrops | 31 (29%) | 22 (40%) | 17 (38%) | 0.30 |
Cromone eyedrops | 25 (23%) | 16 (29%) | 12 (27%) | 0.72 |
Inhaled corticosteroids | 35 (33%) | 27 (49%) | 15 (33%) | 0.10 |
Short acting beta-2 agonists | 16 (15%) | 19 (35%) | 11 (24%S) | 0.02 |
Long acting beta-2 agonists | 2 (2) | 3 (5) | 3 (7) | 0.29 |